Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

Lexaria Bioscience Corp improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods. The Company's technology can be applied to ingestible product formats such as foods, beverages, oral suspensions, tablets, and capsules. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio.

<ul><li>Lexaria is a biotechnology company seeking to enhance the bioavailability of multiple drug agents using DehydraTECH (DHT), its technology using oral and topical delivery.</li><li>It combines lipophilic APIs with specific fatty acid and carrier compounds followed by dehydration.</li><li>DHT offers several attractive features: substantial improvement in bioabsorption in terms of time to measurable plasma levels & AUC, brain permeation, taste masking & side effect reduction.</li></ul>

Lexaria is a biotechnology company seeking to enhance the bioavailability of multiple drug agents using DehydraTECH (DHT), its technology using oral and topical delivery.It combines lipophilic APIs with specific fatty acid and carrier compounds followed by dehydration.DHT offers several attractive features: substantial improvement in bioabsorption in terms of time to measurable plasma levels & AUC, brain permeation, taste masking & side effect reduction.

Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Market & Forensics Analyst

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Thematic (Sector/Industry)

<ul>
<li>The Economic Survey 2024 emphasizes long-term strategies for India's "Amrit Kaal" goals, highlighting sustained economic growth, climate action, and sectoral advancements.</li>
<li>India's GDP grew by 8.2% in FY24, with key sectors like agriculture, manufacturing, and electronics showing strong performance. The government focuses on bottom-up reforms for sustained growth.</li>
<li>The survey's emphasis on strategic, long-term growth and resilience reinforces confidence in India's economic future, aligning with the vision for a "Viksit Bharat" by 2047.</li>
</ul>


The Economic Survey 2024 emphasizes long-term strategies for India's "Amrit Kaal" goals, highlighting sustained economic growth, climate action, and sectoral advancements.
India's GDP grew by 8.2% in FY24, with key sectors like agriculture, manufacturing, and electronics showing strong performance. The government focuses on bottom-up reforms for sustained growth.
The survey's emphasis on strategic, long-term growth and resilience reinforces confidence in India's economic future, aligning with the vision for a "Viksit Bharat" by 2047.


All You Need to Know: Economic Survey 2023-24

<ul>
<li>The Union Budget 2024 expectations: Focuse on job creation, rural support, and domestic manufacturing, aiming to drive economic growth and self-reliance.</li>
<li>Employment, housing and Manufacturing will be the key priorities for Modi 3.O.</li>
<li>This Budget can see some Taxation benefits for middle-class salaried individuals by offering improved tax incentives and a simpler tax system.</li>
</ul>


The Union Budget 2024 expectations: Focuse on job creation, rural support, and domestic manufacturing, aiming to drive economic growth and self-reliance.
Employment, housing and Manufacturing will be the key priorities for Modi 3.O.
This Budget can see some Taxation benefits for middle-class salaried individuals by offering improved tax incentives and a simpler tax system.


Union Budget 2024 Expectations: The Modi 3.0 Era and Its Impact on India's Economic Growth

<ul>
<li>The US Biosecure Act may restrict federal sourcing from China, boosting India's pharmaceutical manufacturing.</li>
<li>India's CDMO market is expected to double in three years, significantly enhancing global competitiveness.</li>
<li>Strategic investments in India's pharmaceutical sector now appear more promising and potentially lucrative.</li>
</ul>


The US Biosecure Act may restrict federal sourcing from China, boosting India's pharmaceutical manufacturing.
India's CDMO market is expected to double in three years, significantly enhancing global competitiveness.
Strategic investments in India's pharmaceutical sector now appear more promising and potentially lucrative.


The Impact of the US Biosecure Act on India's Pharma Export Market

Head of Research and Global Chief Strategist, Steno Research

Andreas Steno

Head of Research and Global Chief Strategist

Macro and Geopolitical Research House

Steno Research

Steno Research is a new macro and geopolitical research house. We are based out of Copenhagen, Denmark, but have an international team and a strong network of sources and partners around the world. The team is lead by Andreas Steno, previous global head of strategy at Nordea Bank, and Mikkel Rosenvold, former chief consultant in the Danish Ministry of Finance.

Cross Asset Strategy

<ul><li>Today, I am going to address three main topics of concern for investors given the current conflicting signals from the US economy.</li><li>These are the key questions I will address, and I will summarize both the pros and cons of each viewpoint, including my own bottom line: Is liquidity no longer improving, but rather at risk of weakening in the coming months? Is the economy accelerating rather than slowing? Is the commodity complex heavily undervalued or overvalued?</li><li>The equity rotation paired with the sharp sell-off in Tech has had me thinking, and we therefore need to litmus-test every corner of our current thesis. Follow along below.</li></ul>

Today, I am going to address three main topics of concern for investors given the current conflicting signals from the US economy.These are the key questions I will address, and I will summarize both the pros and cons of each viewpoint, including my own bottom line: Is liquidity no longer improving, but rather at risk of weakening in the coming months? Is the economy accelerating rather than slowing? Is the commodity complex heavily undervalued or overvalued?The equity rotation paired with the sharp sell-off in Tech has had me thinking, and we therefore need to litmus-test every corner of our current thesis. Follow along below.

Steno Signals #109 – What if We Are All Wrong on Liquidity, Rates and Commodities?

Canada
Insights on Canada

LEXX: GLP-1 Agonist Program Updates

Lexaria is a biotechnology company seeking to enhance the bioavailability of multiple drug agents using DehydraTECH (DHT), its technology using...

Zacks Small Cap Research

All You Need to Know: Economic Survey 2023-24

The Economic Survey'24 outlines India's focus on growth and sectoral advancements to achieve long-term goals & emphasis on reforms for resilience...

Nimish Maheshwari

Union Budget 2024 Expectations: The Modi 3.0 Era and Its Impact on India's Economic Growth

Union Budget 2024 aims to boost job creation, rural support, and domestic manufacturing for economic growth and self-reliance, with focus on...

Nimish Maheshwari

The Impact of the US Biosecure Act on India's Pharma Export Market

The US Biosecure Act may shift federal sourcing from China to India, boosting the country's pharmaceutical manufacturing and global competitiveness.

Nimish Maheshwari

Steno Signals #109 – What if We Are All Wrong on Liquidity, Rates and Commodities?

I am going to address three main topics of concern for investors given the current conflicting signals from the US economy.

Steno Research

LEXX: GLP-1 Agonist Program Updates

Lexaria is a biotechnology company seeking to enhance the bioavailability of multiple drug agents using DehydraTECH (DHT), its technology using...

Zacks Small Cap Research

All You Need to Know: Economic Survey 2023-24

​The Economic Survey'24 outlines India's focus on growth and sectoral advancements to achieve long-term goals & emphasis on reforms for resilience...

Nimish Maheshwari

Union Budget 2024 Expectations: The Modi 3.0 Era and Its Impact on India's Economic Growth

​Union Budget 2024 aims to boost job creation, rural support, and domestic manufacturing for economic growth and self-reliance, with focus on...

Nimish Maheshwari

The Impact of the US Biosecure Act on India's Pharma Export Market

​The US Biosecure Act may shift federal sourcing from China to India, boosting the country's pharmaceutical manufacturing and global competitiveness.

Nimish Maheshwari

Steno Signals #109 – What if We Are All Wrong on Liquidity, Rates and Commodities?

I am going to address three main topics of concern for investors given the current conflicting signals from the US economy.

Steno Research

The Economic Survey'24 outlines India's focus on growth and sectoral advancements to achieve long-term goals & emphasis on reforms for resilience...

Union Budget 2024 aims to boost job creation, rural support, and domestic manufacturing for economic growth and self-reliance, with focus on...

The US Biosecure Act may shift federal sourcing from China to India, boosting the country's pharmaceutical manufacturing and global competitiveness.